Antibodies targeting SIRP alpha and uses thereof

By developing high-affinity and specific antagonistic SIRPα antibodies, the problem of insufficient affinity and activity of existing antibodies in treating tumors is solved, the phagocytosis of tumor cells is enhanced, the toxicity to normal cells is reduced, and the therapeutic effect is improved. Security.

CN119032108APending Publication Date: 2024-11-26BIOSION INC

Patent Information

Application Number
CN202380034177.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-20
Filing Date
2023-04-20
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing SIRPα blocking antibodies have problems with insufficient affinity and activity when treating tumors, and are toxic to normal cells, affecting efficacy and safety.

Method used

An antagonistic SIRPα antibody or antigen-binding portion thereof has been developed, with a specific binding SIRPα, high affinity and blocking activity, capable of cross-reacting with SIRPβ, but does not bind SIRPγ and mouse SIRPα, for enhancing macrophage pairs phagocytic activity of tumor cells.

Benefits of technology

It improves the binding affinity and blocking activity of SIRPα for humans and monkeys, reduces the toxicity to normal cells, enhances the phagocytosis of tumor cells, and improves the anti-tumor activity in the body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005084070310000121
    Figure BDA0005084070310000121
  • Figure BDA0005084070310000311
    Figure BDA0005084070310000311
  • Figure BDA0005084070310000312
    Figure BDA0005084070310000312
Patent Text Reader

Abstract

The invention provides an isolated monoclonal antibody which specifically binds to human SIRP alpha, or an antigen binding part thereof. Nucleic acid molecules encoding the antibodies or antigen-binding portions thereof, expression vectors, host cells and methods for expressing the antibodies or antigen-binding portions thereof are also provided. Also provided are bispecific molecules, immunoconjugates, chimeric antigen receptors, oncolytic viruses, and pharmaceutical compositions comprising the antibodies or antigen-binding portions thereof, as well as methods of treatment using the SIRP alpha antibodies or antigen-binding portions thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Method for the production of non-immunogenic proteins

    US20030153043A1

  • Cells of which genome is modified

    US20040110704A1

  • Chemical linkers and conjugates thereof

    US20060024317A1

  • Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials

    US4399216A

  • Osmotic drug delivery system

    US4439196A

Cited By

  • SMCP polyclonal antibody as well as preparation method and application thereof

    CN120943955A